Facebook, Inc. (NASDAQ:FB) (Los Angeles Times)
Facebook Inc.’s stock tumbled Monday after the social media company accused a data analytics firm used by the Trump campaign of exploiting ill-gotten data belonging to unwitting Facebook users. Shares of Facebook sank 6.7% to $172.69 around 9:50 a.m. Pacific time. On Friday, a Facebook executive said in a blog post that the Menlo Park, Calif., company was suspending data analytics firm Strategic Communication Laboratories and its affiliate Cambridge Analytica. Facebook said the two companies had failed to delete user data it had acquired in 2015 in violation of the platform’s rules.
Geron Corporation (NASDAQ:GERN) (The Motley Fool)
What happened: Shares of Geron Corporation (NASDAQ:GERN), a clinical-stage biotech developing a cancer therapy, popped this morning after the company included a pipeline update with its fourth-quarter earnings report after Friday’s bell. The improved outlook for imetelstat has pushed the stock 28.8% higher as of 11:29 a.m. EDT on Monday.
Heron Therapeutics Inc (NASDAQ:HRTX) (MarketWatch)
Heron Therapeutics Inc.’s shares HRTX, +26.98% surged 28% in premarket trade Monday, after the company announced positive results in a late-stage trial of an anesthetic used for patients undergoing bunionectomy and hernia repair. The company said the trial of its HTX-011 agent showing significant reductions in pain intensity and use of opioids afterachieved all primary and key secondary endpoints in two Phase 3 trials, surgery.
Micro Focus International PLC – ADR (NYSE:MFGP) (The Wall Street Journal)
LONDON—Micro Focus International PLC’s $8.8 billion merger with Hewlett Packard Enterprise Co.’s software business represented a rarity 18 months ago: a British tech company taking over a foreign one, rather than the other way around. It hasn’t worked out as planned. Micro Focus shares fell by as much as 55% Monday, wiping about £4.5 billion ($6.3 billion) off its market value, after it said technical problems related to combining the computer systems of Micro Focus and HPE would lead to lower-than-expected sales.